Neira Sáinz

Dr. Neira Sáinz


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Metabolism
Verified
Journal Article
Closed access
NSNeira Sáinz
Neira Sáinz
JBJaione Barrenetxe
Jaione Barrenetxe
MMMaria J. Moreno-Aliaga
Maria J. Moreno-Aliaga
JMJ. Alfredo Martinez
J. Alfredo Martinez

24 February 2009 in International Journal of Obesity
Verified
Journal Article
Closed access
ARAmaia Rodríguez
Amaia Rodríguez
Javier Gomez-AmbrosiJavier Gomez-Ambrosi
Javier Gomez-Ambrosi
Victoria CatalánVictoria Catalán
Victoria Catalán
MGM J Gil
M J Gil
SBSara Becerril
Sara Becerril
GFGema Frühbeck
Gema Frühbeck

1 August 2009 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
GFGema Frühbeck
Gema Frühbeck
SBSara Becerril
Sara Becerril
NSNeira Sáinz
Neira Sáinz
PGPuy Garrastachu
Puy Garrastachu
MGMaria Garcia-Velloso
Maria Garcia-Velloso

4 September 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NSNeira Sáinz
Neira Sáinz
ARAmaia Rodríguez
Amaia Rodríguez
Victoria CatalánVictoria Catalán
Victoria Catalán
SBSara Becerril
Sara Becerril
BRBeatriz Ramírez
Beatriz Ramírez
GFGema Frühbeck
Gema Frühbeck
Absence of leptin has been associated with reduced skeletal muscle mass in leptin-deficient ob/ob mice. The aim of our study was to examine the effect of leptin on the catabolic and anabolic pathways regulating muscle mass. Gastrocnemius, extensor digitorum longus and soleus muscle mass as well as fiber size were significantly lower in ob/ob mice compared to wild type littermates, being significantly increased by leptin administration (P<0.001). This effect was associated with an inactivation of the muscle atrophy-related transcription factor forkhead box class O3 (FoxO3a) (P<0.05), and with a decrease in the protein expression levels of the E3 ubiquitin-ligases muscle atrophy F-box (MAFbx) (P<0.05) and muscle RING finger 1 (MuRF1) (P<0.05). Moreover, leptin increased (P<0.01) protein expression levels of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), a regulator of muscle fiber type, and decreased (P<0.05) myostatin protein, a negative regulator of muscle growth. Leptin administration also activated (P<0.01) the regulators of cell cycle progression proliferating cell nuclear antigen (PCNA) and cyclin D1, and increased (P<0.01) myofibrillar protein troponin T. The present study provides evidence that leptin treatment may increase muscle mass of ob/ob mice by inhibiting myofibrillar protein degradation as well as enhancing muscle cell proliferation.

9 September 2014 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
ARAmaia Rodríguez
Amaia Rodríguez
SBSara Becerril
Sara Becerril
LML Méndez-Giménez
L Méndez-Giménez
BRB Ramírez
B Ramírez
NSNeira Sáinz
Neira Sáinz
GFG Frühbeck
G Frühbeck

10 February 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
LMLeyre Martínez-Fernández
Leyre Martínez-Fernández
PGPedro González-Muniesa
Pedro González-Muniesa
LLLaura M. Laiglesia
Laura M. Laiglesia
NSNeira Sáinz
Neira Sáinz
PPPedro L. Prieto-Hontoria
Pedro L. Prieto-Hontoria
MMMaria J. Moreno-Aliaga
Maria J. Moreno-Aliaga
The beneficial actions of n‐3 fatty acids on obesity‐induced insulin resistance and inflammation have been related to the synthesis of specialized proresolving lipid mediators (SPMs) like resolvins. The aim of this study was to evaluate the ability of one of these SPMs, maresin 1 (MaR1), to reverse adipose tissue inflammation and/or insulin resistance in two models of obesity: diet‐induced obese (DIO) mice and genetic (ob/ob) obese mice. In DIO mice, MaR1 (2 mg/kg; 10 d) reduced F4/80‐positive cells and expression of the proinflammatory M1 macrophage phenotype marker Cd11c in white adipose tissue (WAT). Moreover, MaR1 decreased Mcp‐1, Tnf‐a, and Il‐1b expression, upregulated adiponectin and Glut‐4, and increased Akt phosphorylation in WAT. MaR1 administration (2 mg/kg; 20 d) to ob/ob mice did not modify macrophage recruitment but increased the M2 macrophage markers Cd163 and Il‐10. MaR1 reduced Mcp‐1, Tnf‐a, Il‐1b, and Dpp‐4 and increased adiponectin gene expression in WAT. MaR1 treatment also improved the insulin tolerance test of ob/ob mice and increased Akt and AMPK phosphorylation in WAT. These data suggest that treatment with MaR1 can counteract the dysfunctional inflamed WAT and could be useful to improve insulin sensitivity in murine models of obesity.—Martínez‐Fernández, L., González‐Muniesa, P., Laiglesia, L. M., Sáinz, N., Prieto‐Hontoria, P. L., Escoté, X., Odriozola, L., Corrales, F. J., Arbones‐Mainar, J. M., Martínez, J. A., Moreno‐Aliaga, M. J. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet‐induced obese mice. FASEB J. 31, 2135–2145 (2017). www.fasebj.org